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Abstract
It is accepted that a lumbar puncture (LP) and cerebrospinal fluid (CSF) biomarker analysis support the routine
diagnostic work-up for the differential diagnosis of dementia due to Alzheimer’s disease (AD) within certain patient
cohorts . These tests, which measure CSF protein concentrations of amyloid-β  (Aβ ), total tau (t-tau) and phospho tau
(p-tau), were recently validated, accredited and made available clinically for the first time in Ireland. A working group,
comprising Irish clinical and scientific researchers, met to review a) the validation results; b) international consensus
opinions, and c) research and clinical evidence as to the clinical utility of CSF biomarker analysis for AD dementia
diagnosis. The outcome of this meeting was the formulation of a consensus statement paper for the benefit of health care
professionals involved in the diagnosis and management of dementia to ensure appropriate use of these biomarker tests in
clinical settings in Ireland.
Introduction
A diagnostic biomarker possessing good sensitivity and specificity can support AD diagnosis and lower the probability of
false negative or false positive test results particularly when trying to rule out non-AD dementias . Traditionally AD
diagnosis has been made using the National Institute of Neurological and Communicative Disorders and Stroke and
Alzheimer’s disease and Related Disorders Association (NINDS-ADRA) criteria  which have a reported average
sensitivity and specificity of 81% and 70% respectively . This indicates that in some cases these criteria , if used without
additional diagnostic supports, may identify individuals as having AD when in fact they may have a non-AD dementias .
CSF biomarker analysis and neuroimaging biomarker platforms have proven sensitivity and specificity for discriminating
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for AD dementia and have, along with several other biomarkers, been recommended as diagnostic adjuncts in the recently
revised National Institute on Aging and Alzheimer’s Association’s (NIA-AA) research diagnostic criteria for AD
dementia  (Table 1). Aβ , t-tau and p-tau are recognised as the most informative of all CSF biomarkers in relation to
their analytical sensitivity and specificity for the diagnosis of AD . They mirror the pathophysiology of AD with
decreased CSF Aβ and increased CSF t-tau and p-tau concentrations reflecting increased amyloid plaque load in the
brain parenchyma, and neuronal degeneration and neurofibrillary tangle formation respectively, expected changes in AD
CSF biomarker levels are such that Aβ concentrations decrease to around 50% of control levels and t-tau and p-tau CSF
concentrations increase by 200-300% over controls (as reviewed by Blennow et al., 2015) . CSF Aβ  concentration is
inversely related to Aβ plaque load levels as measured in living brain biopsies  and p-tau and t-tau CSF concentrations
reflect the scale of degenerative neuronal AD-pathology. In addition, very high t-tau CSF concentrations are closely
associated with more rapid advancement to AD and increased death rates .
Magnetic resonance imaging (MRI) and computed tomography (CT) demonstrate atrophy of the hippocampus and
temporal cortex and fluorodeoxyglucose-positron emission tomography (FDG-PET) shows neuronal functional decline as
represented by hypometabolism of the parietotemporal lobe and posterior cingulate gyrus in AD affected brains .
Structural imaging (MRI, CT) allows for the exclusion of non-AD diseases, and MRI can be helpful for observing disease
progression over time , FDG-PET on the other hand lends itself to increasing diagnostic certainty with a reported
specificity of 95% for supporting the differential diagnosis of other dementias .
While widely accepted as research tools, challenges exist regarding the use of CSF biomarker testing in clinical settings; at
the fore lies a lack of standardisation with respect to its execution and analysis. Reports to date have shown that the most
established assay platforms for measuring CSF biomarkers perform well at a local level with an intra-laboratory variation
of around 10% .  However inter-laboratory variation at 20-30% is unacceptably high, and renders the interpretation of
assay data across clinical or research facilities difficult .  To overcome this issue it has been recommended that each
laboratory develop its own CSF biomarker reference ranges and cut-off values, pertinent to the relevant local population,
using well defined subject recruitment criteria and data/sample collection methodologies .  Secondly, at present there are
no guidelines as to when each of the biomarkers, imaging, and CSF could be used to best effect during the dementia
diagnostic process, whether they should assessed in parallel to maximise sensitivity and specificity or in isolation (as
reviewed by Blennow et al., 2015) . However, it has been reported that their ability to discriminate for AD significantly
increases when they are used in combination . 
Finally, other issues include a lack of defined indications for the clinical use of CSF biomarker analysis and guidelines on
interpreting test results; moreover the lack of a long-term AD related disease modifying therapy strengthens the argument
that it is potentially psychologically harmful to diagnose an individual at the very early or pre-dementia stages of AD.
However, it has been reported that early diagnosis provides patients with relief and that there is substantial interest in early
diagnostic testing in the public arena . Furthermore, obtaining a diagnosis can allow patients to plan for the future in
an informed manner and, importantly, assessment can detect treatable or reversible causes of memory disorders. To date,
published consensus recommendations have focused on CSF biomarkers being used in cases of uncertain aetiology,
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atypical presentation or early onset neurodegeneration or dementia as it is felt that the standard assessment criteria should
be sufficient to delineate typical cases of AD dementia. Most guidelines recognise the utility of measuring Aβ , t-tau and
p-tau in combination with routine diagnostic methods .
Methods
A working group comprising members of the Irish Network for Biomarkers in Neurodegeneration (IN-BIND), Irish
neurologists, geriatricians, geriatric psychiatrists, neuropsychologists, neuro-radiologists, medical laboratory scientists and
a representative of the Alzheimer Society of Ireland met to discuss CSF biomarker analysis for dementia diagnosis to
produce consensus statement recommendations for Irish health care professionals involved in the diagnosis and
management of dementia (Summarised Table 2) The working group identified the most salient issues concerning the use
of CSF biomarkers in clinical settings and discussed these points in the context of CSF biomarker testing recently
becoming available in Ireland and with reference to international consensus recommendations and supporting scientific
publications.
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Results
Consensus Procedural Recommendations
Indications
The majority of cases of dementia can be accurately diagnosed using standard assessment which involves clinical history
(including collateral), physical and neurological examination, routine blood tests to exclude treatable/reversible causes [
FBC, Renal, Liver, Bone profiles, Thyroid function tests, vitamin B12, folate], structural neuroimaging (CT or MRI
preferable, with volumetric 3D sequence and coronal reformats for assessment of medial temporal lobes and hippocampal
volume estimation) and neuro-cognitive testing (ideally cognitive testing should include evaluation of executive function,
language, praxis, visuospatial and memory functions).
Where the standard assessment does not result in delineating the cause of the cognitive disorder, or in the case of rapidly
progressive, young onset and atypical presentations, further functional neuroimaging (FDG PET) and/or LP for CSF
analysis for the core AD biomarkers should be considered. Aβ , t-tau and p-tau are the recommended biomarkers to
support the diagnosis of dementia due to AD. Where DLB is a possibility, a 123I-FP-CIT single photon emission
computed tomography (SPECT) (aka DaT) scan is a useful functional neuroimaging test . In individuals with MCI,
where the person wishes to know whether the cause of their memory complaint is possibly due to AD, biomarker analysis
can be carried out following discussion between physician and patient on limitations of use in this context. CSF biomarker
testing is not indicated in asymptomatic or genetically at-risk individuals. The recommendation for CSF biomarker testing
should only be made in specialist settings by clinicians who are familiar with the testing and can interpret the results in
the 
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context of a comprehensive patient assessment (Figure 1)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarker results interpretation
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Sufficient sensitivity and specificity for CSF analysis and biomarker cut points is required to ensure an accurate AD
diagnosis, and the value of a negative result cannot be understated. The working group recommendations indicate that CSF
acquisition and processing be carried out according to standardised validated protocols (Table 3); that AD CSF biomarker
analysis be carried out at a certified facility again according to standardised methodologies; that biomarker feedback
include all three AD biomarkers (Aβ , t-tau and p-tau) and that test results be assessed within the clinical context.
Furthermore, following a review of the literature, the working group recommends that the following interpretation be
applied to CSF biomarker results; in cases where pathological changes in all 3 CSF biomarkers are observed the CSF
biomarker profile can be considered ‘neurochemically compatible’ with a diagnosis of AD and vice versa, if no
pathological changes in the 3 CSF biomarkers are observed this result is considered ‘neurochemically incompatible’ with a
diagnosis of AD. Moreover, CSF biomarker results in any other combination have been described as non-informative in
relation to an AD diagnosis and further investigation is advised . Finally, it is also recommended that results should be
supported by an explanatory statement  and that decisions on diagnosis should be made collectively)
 
Informed decision making, patient information and feedback
Bearing in mind that the person in question has a cognitive impairment , and possible dementia , clinicians need to be
mindful that all information pertaining to the test be as accessible as possible and that it may need to be conveyed to the
individual a number of times, therefore , regular checking for understanding is recommended. Clinicians must also be
sensitive to the level of information wanted by the patient and tailoring of information for each patient is advised. In
advance of testing patients should be advised firstly, that the test is an adjunct to the diagnosis of AD, improving the
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clinicians’ confidence of the diagnosis when added to all other clinical and testing information; and secondly, that the
result may or may not support the diagnosis of AD and may prove inconclusive.
Final diagnosis must be informed by the entire assessment process and other test results, including the CSF biomarker
results. Best practice indicates that disclosure should not be a once-off process and again for each person the process of
disclosure, being mindful of the patient’s perspective, may differ. Results should be clearly explained in the context of
their overall clinical picture.
Discussion
The IN-BIND working group consensus recommendations support the clinical use of CSF biomarker analysis in the
delineation of dementia due to AD. Clinical and research evidence shows CSF biomarkers have a high degree of
sensitivity and specificity for AD and their capacity to positively contribute to the AD dementia diagnosis process, by
increasing clinician confidence and supporting diagnostic accuracy in certain clinical situations, has been proven. Indeed,
a comparison of the sensitivity of various biomarker platforms to discriminate for AD showed that MRI, CBF-SPECT,
FDG-PET and CSF biomarkers performed with equal sensitivity in cases of moderate dementia; that CSF biomarkers and
FDG-PET performed best in cases of mild dementia and CSF biomarkers alone performed best in cases classed as being of
questionable dementia or mild cognitive impairment (clinical dementia rating 0.5) . Moreover, CSF biomarkers have
proven diagnostic accuracy and discriminatory capacity displaying 85% concordance with neuropathological and clinical
evaluations and 90% capacity to distinguish between AD patients and controls .  However, it is important to recognise
that the specificity of the CSF biomarkers is lower for other dementias due to confounding factors such as underlying
mixed pathologies or comorbidities .
However, despite the acknowledged contribution that CSF biomarker analysis can make to the AD dementia diagnostic
process, variation exists in the awareness of, and in attitudes and practices relating to, CSF biomarker analysis within and
between countries across Europe. This disparity is recognised as one of the main barriers to their acceptance in clinical
settings. In this context the IN-BIND consensus process highlighted the need for a clear defined pathway for clinicians as
to how to incorporate CSF testing into the AD dementia diagnostic process, as well as the requirement for the
dissemination of well-defined protocols for the appropriate handling and processing of CSF samples. The working group’s
recommendations provide a framework to guide practitioners as to the appropriate use of, and standardised application of,
CSF biomarker analysis for the differential diagnosis of AD dementia in Ireland.
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